Preferred and actual place of death in haematological malignancy.

Howell, D A; Wang, H I; Roman, E; Smith, A G; Patmore, R; Johnson, M J; Garry, A; Howard, M

Howell, D A; Wang, H I; Roman, E; Smith, A G; Patmore, R; Johnson, M J; Garry, A; Howard, M.

Affiliation

Howell DA; Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
Wang HI; Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
Roman E; Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
Smith AG; Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
Patmore R; Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Hull, UK.
Johnson MJ; Hull York Medical School, University of Hull, Hull, UK.
Garry A; York Teaching Hospital NHS Foundation Trust, York, UK.
Howard M; York Teaching Hospital NHS Foundation Trust, York, UK.

BMJ Support Palliat Care ; 7(2): 150-157, 2017 Jun.

Article de En | MEDLINE | ID: mdl-26156005

Sujet(s)
Mots clés

Actual place of death; Haematological malignancy; Lymphoma; Myeloma; Preferred place of death

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Attitude envers la mort / Tumeurs hématologiques / Préférence des patients Type d'étude: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limites: Female / Humans / Male Pays/Région comme sujet: Europa Langue: En Journal: BMJ Support Palliat Care Année: 2017 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google